Merck KGaA Earnings Miss Estimates on Cancer Drug Research

Updated on

Merck KGaA’s first-quarter earnings missed analyst estimates as the German manufacturer of drugs and specialty materials spent more on marketing and research as it tries to reinvigorate its pharmaceutical business.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.